Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions
暂无分享,去创建一个
R. Collins | R. Peto | S. Parish | J. Armitage | P. Sleight
[1] M. Hennerici,et al. Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study , 2003, Cerebrovascular Diseases.
[2] Mark Woodward,et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. , 2003, International journal of epidemiology.
[3] P. Doraiswamy,et al. Statin‐Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature , 2003, Pharmacotherapy.
[4] N J Wald,et al. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.
[5] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[6] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[7] Robert Clarke,et al. Utility of TICS‐M for the assessment of cognitive function in older adults , 2003, International journal of geriatric psychiatry.
[8] Barry R. Davis,et al. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.
[9] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[10] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[11] J. Hallas,et al. Statins and risk of polyneuropathy: A case-control study , 2002, Neurology.
[12] Kenneth Rockwood,et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.
[13] V. Athyros,et al. Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.
[14] P. Amarenco. Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction , 2001, Neurology.
[15] P. Sandercock. Statins for stroke prevention? , 2001, The Lancet.
[16] R. Collins,et al. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.
[17] B. Davis,et al. Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.
[18] P. Wolf,et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. , 2001, Circulation.
[19] H Jick,et al. Statins and the risk of dementia , 2000, The Lancet.
[20] P Glasziou,et al. Pravastatin therapy and the risk of stroke. , 2000, The New England journal of medicine.
[21] G. Tognoni,et al. Cholesterol Reduction and Stroke Occurrence: An Overview of Randomized Clinical Trials , 2000, Cerebrovascular Diseases.
[22] P A Wolf,et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack : a statement for healthcare professionals from the Stroke Council of the American Heart Association. , 1999, Stroke.
[23] Z. Li,et al. Blood pressure, cholesterol, and stroke in eastern Asia , 1998, The Lancet.
[24] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[25] C. Hennekens,et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.
[26] Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.
[27] D. Kromhout. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.
[28] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[29] D. Reed,et al. Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men. , 1995, JAMA.
[30] M. Schroll,et al. Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. , 1995, Stroke.
[31] C. Furberg,et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.
[32] C. Hennekens,et al. An overview of trials of cholesterol lowering and risk of stroke. , 1995, Archives of internal medicine.
[33] C. Furberg,et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.
[34] J. Neaton,et al. Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.
[35] S. Yusuf,et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.
[36] R Peto,et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. , 1991, BMJ.
[37] D. Jacobs,et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.
[38] A. V. Peterson,et al. Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort. , 1984, Journal of chronic diseases.
[39] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[40] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.